About Yecuris
Yecuris is a Healthcare company based in Tualatin (United States) founded in 2007, and was acquired by Janiver Labs in January 2024. It operates as a humanized liver rodent models are developed for biology research. Yecuris has raised $1.25 million across 5 funding rounds from investors including HHS and Janiver Labs. The company has 26 employees. Yecuris offers products and services including FRG Platform, Fresh Hepatocytes, and Viral Hepatitis Research Services. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is Yecuris Corporation. Its competitors include Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Yecuris is developing humanized liver rodent models called FRG KO in various immunocompromised backgrounds. Apart from animal models and cell lines, the company has also developed a high-content screening platform called MetAbArray, which enables the measurement of up to 10 parameters in a single assay. MetAbArray uses HepG2 cells to run the assays. Additionally, the company develops primary human and mouse hepatocytes (Yecuris HepaCur), and the CuRx line of reagents. The company offers research services to clients in the form of technical support for in-vitro and in-vivo research and development as well as consultancy for the design of animal research facilities.
- Headquarters Tualatin, United States
- Employees 26
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website yecuris.com
- Social LinkedIn X Facebook
- Acquired by Janiver Labs (Jan 2024)
- Legal Name Yecuris Corporation
- Total Equity Funding$1.25M (USD)
in 5 rounds
- Latest Funding Round$453.28K (USD), Grant
Mar 2012
- InvestorsHHS
& 1 more
- Employee Count26
- Acquired byJaniver Labs
(Jan 2024)
Products & Services of Yecuris
Yecuris offers a comprehensive portfolio of products and services, including FRG Platform, Fresh Hepatocytes, and Viral Hepatitis Research Services.
Platform for liver-humanized mice in gene and cell therapy research
Reagents for liver-related disease and metabolism studies
Services for testing hepatotropic agents in preclinical models
Funding Insights of Yecuris
Yecuris has successfully raised a total of $1.25M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $453.28 thousand completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.25M
- Total Rounds 5
- Last Round Grant — $453,281
- First Round $1.25M
(Jul 2009)
- Investors Count 1
All 5 funding rounds of Yecuris with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Yecuris
Yecuris has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Janiver Labs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Animal models for research are supplied with high genetic stability. | 1960 | janvier-labs.com | Loire, France |
Investor details for Yecuris
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Yecuris
4 people are tracked at Yecuris (3 in leadership, 1 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Robert Copenhaver | CEO | Leadership |
Markus Grompe, M.D. | Founder, Scientific Consultant | Leadership |
Devorah (Devo) Goldman | Vice President, Scientific Operations | Leadership |
David Sampson | Research Associate III | Team |
Complete people profiles for Yecuris
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Yecuris
4 dated milestones of Yecuris across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Yecuris is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Grant, of $453K.
- Exit Acquired by Janiver Labs.
Competitors of Yecuris
Yecuris has 10 listed competitors in our database, 8 of them funded. They include Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| exonhit.com | 1997 | Paris, France | $65.46M | – | Fully integrated in vitro diagnostics company specializing in transplantation, infectious diseases and cancer diagnosis | |
| origene.com | 1996 | Rockville, United States | $69.55M | 141 | Proteins, antibodies, and molecular tools are manufactured for research applications. | |
| sangon.com | 2003 | Shanghai, China | $300M | – | Research services, reagents, and kits for biotech applications are provided. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits |
Detailed competitors of Yecuris
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Yecuris
The website of Yecuris (yecuris.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 78.3% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Yecuris (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Yecuris
Complete news archive for Yecuris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Yecuris
Yecuris was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Yecuris is headquartered in Tualatin, United States. It is registered at Tualatin, Oregon, United States.
Yecuris is a funded company, having raised a total of $1.25M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.25M, raised on Jul 2009.
Yecuris has 26 employees.
Yecuris is developing humanized liver rodent models called FRG KO in various immunocompromised backgrounds. Apart from animal models and cell lines, the company has also developed a high-content screening platform called MetAbArray, which enables the measurement of up to 10 parameters in a single assay. MetAbArray uses HepG2 cells to run the assays. Additionally, the company develops primary human and mouse hepatocytes (Yecuris HepaCur), and the CuRx line of reagents. The company offers research services to clients in the form of technical support for in-vitro and in-vivo research and development as well as consultancy for the design of animal research facilities.
Yecuris's top competitors include Abcam, Sino Biological and Meridian Bioscience.
Yecuris offers FRG Platform, Fresh Hepatocytes, and Viral Hepatitis Research Services.
Yecuris has 2 investors. Key investors include HHS, and Janiver Labs.
Yecuris operates through Yecuris Corporation.
Yes. Yecuris was acquired by Janiver Labs in January 2024.